Narcolepsy and Syndromes of Primary Excessive Daytime Somnolence

Excessive daytime sleepiness (EDS) or somnolence is common in our patients and in society in general. The most common cause of EDS is “voluntary” sleep restriction. Other common causes include sleep-fragmenting disorders such as the obstructive sleep apnea syndrome. Somewhat less familiar to the clinician are EDS conditions arising from central nervous system dysfunction. Of these so-called primary disorders of somnolence, narcolepsy is the most well known and extensively studied, yet often misunderstood and misdiagnosed. Idiopathic hypersomnia, the recurrent hypersomnias, and EDS associated with nervous system disorders also must be well-understood to provide appropriate evaluation and management of the patient with EDS. This review summarizes the distinguishing features of these clinical syndromes of primary EDS. A brief overview of the pharmacological management of primary EDS is included. Finally, in view of the tremendous advances that have occurred in the past few years in our understanding of the pathophysiology of canine and human narcolepsy, we also highlight these discoveries.

KEYWORDS

Sleep - narcolepsy - cataplexy - somnolence - excessive daytime sleepiness - hypersomnia

REFERENCES

• 1 Hublin C, Kaprio J, Partinen M et al.. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort.  Ann Neurol. 1994;  35 709-716
• 2 Mignot E. Genetic and familial aspects of narcolepsy.  Neurology. 1998;  50(suppl 1) S16-S22
• 3 International Classification of Sleep Disorders (ICSD) . Diagnostic and Coding Diagnostic Classification Steering Committee (Thorpy MJ, chairman). American Sleep Disorders Association.  Narcolepsy. 1990;  347 38-43
• 4 Beusterien K M, Rogers A E, Walsleben J A et al.. Health-related quality of life effects of modafinil for treatment of narcolepsy.  Sleep. 1999;  22 757-765
• 5 US Xyrem in Narcolepsy Multi-center Study Group . A randomized, double blind, placebo controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.  Sleep. 2002;  25 42-49
• 6 Johns M W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale.  Sleep. 1991;  14 540-545
• 7 Honda Y. Clinical features of narcolepsy: Japanese experiences. In: Honda Y, Juji T HLA in Narcolepsy Berlin; Springer-Verlag 1988: 24-57
• 8 Gelb M, Guilleminault C, Kraemer H et al.. Stability of cataplexy over several months: information for the design of therapeutic trials.  Sleep. 1994;  17 265-273
• 9 Overeem S, Mignot E, van Dijk J G, Lammers G J. Narcolepsy: clinical features, new pathophysiological insights, and future perspectives.  J Clin Neurophysiol. 2001;  18 78-105
• 10 Nishino S, Ripley B, Overeem S, Lammers G J, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy.  Lancet. 2000;  355 39-40
• 11 Mignot E, Lammers G J, Ripley B et al.. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.  Arch Neurol. 2002;  59 1553-1562
• 12 Mignot E. Genetic and familial aspects of narcolepsy.  Neurology. 1998;  50 S16-S22
• 13 Guilleminault C, Stoohs R, Clerk A, Cetel M, Maistros P. A cause of excessive daytime sleepiness. The upper airway resistance syndrome.  Chest. 1993;  104 781-787
• 14 Roth B. Narcolepsy and hypersomnia.  Schweiz Arch Neurol Neurochir Psychiatr. 1976;  119 31-41
• 15 Aldrich M S. The clinical spectrum of narcolepsy and idiopathic hypersomnia.  Neurology. 1996;  46 393-401
• 16 Montplaisir J, Poirier G. HLA in disorders of excessive sleepiness without cataplexy in Canada. In: Honda Y, Juji T HLA in Narcolepsy Berlin; Springer-Verlag 1988: 186
• 17 Montplaisir J, De Champlain J, Young S N et al.. Narcolepsy and idiopathic hypersomnia: biogenic amines and related compounds in CSF.  Neurology. 1982;  32 1299-1302
• 18 Faull K F, Guilleminault C, Berger P A, Barchas J D. Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia.  Ann Neurol. 1983;  13 258-263
• 19 Faull K F, Thiemann S, King R J, Guilleminault C. Monoamine interactions in narcolepsy and hypersomnia: a preliminary report.  Sleep. 1986;  9 246-249
• 20 Bruck D, Parkes J D. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data.  J Neurol Neurosurg Psychiatry. 1996;  60 576-578
• 21 Bassetti C, Aldrich M S. Idiopathic hypersomnia. A series of 42 patients.  Brain. 1997;  120 1423-1435
• 22 Billiard M, Dauvilliers Y. Idiopathic hypersomnia.  Sleep Med Rev. 2001;  5 349-358
• 23 Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with “sleep drunkenness”.  Arch Gen Psychiatry. 1972;  26 456-462
• 24 Sforza E, Gaudreau H, Petit D, Montplaisir J. Homeostatic sleep regulation in patients with idiopathic hypersomnia.  Clin Neurophysiol. 2000;  111 277-282
• 25 Sangal R B, Sangal J M. P300 latency: abnormal in sleep apnea with somnolence and idiopathic hypersomnia, but normal in narcolepsy.  Clin Electroencephalogr. 1995;  26 146-153
• 26 Critchley M. The syndrome of hypersomnia and periodical megaphagia in the adult male (Kleine-Levin): what is its natural course?.  Rev Neurol. 1967;  116 647-650
• 27 Rosenow F, Kotagal P, Cohen B H, Green C, Wyllie E. Multiple sleep latency test and polysomnography in diagnosing Kleine-Levin syndrome and periodic hypersomnia.  J Clin Neurophysiol. 2000;  17 519-522
• 28 Arias M, Crespo Iglesias J M, Perez J, Requena-Caballero I, Sesar-Ignacio A, Peleteiro-Fernandez M. Klein-Levin syndrome: contribution of brain SPECT in diagnosis.  Rev Neurol. 2003;  35 531-533
• 29 Billiard M, Guilleminault C, Dement W C. A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or a new clinical entity?.  Neurology. 1975;  25 436-443
• 30 Sachs C, Persson H, Hagenfeldt K. Menstruation-associated periodic hypersomnia: a case study with successful treatment.  Neurology. 1982;  32 1376-1379
• 31 Bamford C R. Menstrual-associated sleep disorder: an unusual hypersomniac variant associated with both menstruation and amenorrhea with a possible link to prolactin and metoclopramide.  Sleep. 1993;  16 484-486
• 32 Rothstein J D, Guidotti A, Tinuper P et al.. Endogenous benzodiazepine receptor ligands in idiopathic recurring stupor.  Lancet. 1992;  340 1002-1004
• 33 Lugaresi E, Montagna P, Tinuper P et al.. Endozepine stupor. Recurring stupor linked to endozepine-4 accumulation.  Brain. 1998;  121 127-133
• 34 Soriani S, Carrozzi M, De Carlo L et al.. Endozepine stupor in children.  Cephalalgia. 1997;  17 658-661
• 35 Francisco G E, Ivanhoe C B. Successful treatment of post-traumatic narcolepsy with methylphenidate: a case report.  Am J Phys Med Rehabil. 1996;  75 63-65
• 36 Manni R, Tantara A. Evaluation of sleepiness in epilepsy.  Clin Neurophysiol. 2000;  111(suppl 2) S111-S114
• 37 Toth L A, Opp M R. Sleep and infection. In: Lee-Chiong TL, Sateia MJ, Carskadon MA Sleep Medicine Philadelphia; Hanley & Belfus 2002: 77-83
• 38 Guilleminault C, Mondini S. Mononucleosis and chronic daytime sleepiness: a long term follow-up study.  Arch Intern Med. 1986;  146 1333-1335
• 39 Askenasy J JM. Sleep in Parkinson’s disease.  Acta Neurol Scand. 1993;  87 167-170
• 40 Chokroverty S. Sleep and degenerative neurologic disorders.  Neurol Clin. 1996;  14 807-826
• 41 Trenkwalder C. Sleep dysfunction in Parkinson’s disease.  Clin Neurosci. 1998;  5 107-114
• 42 George C FP. Neuromuscular disorders. In: Kryger MH, Roth T, Dement WC Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia; WB Saunders Co 2000: 1087-1092
• 43 Gibbs J W, Ciafaloni E, Radtke R A. Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy.  Sleep. 2002;  25 672-675
• 44 Mitler M M, Aldrich M S, Koob G F, Zarcone V P. Narcolepsy and its treatment with stimulants. ASDA Standards of Practice.  Sleep. 1994;  17 352-371
• 45 US Modafinil in Narcolepsy Multicenter Study Group . Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy.  Neurology. 2000;  54 1166-1175
• 46 US Modafinil in Narcolepsy Multicenter Study Group . Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy.  Ann Neurol. 1998;  43 88-97
• 47 Tunnicliff G, Cash C D. Gamma-hydroxybutyrate: Molecular, Functional and Clinical Aspects. New York; Taylor and Francis 2002
• 48 Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy.  Prog Neurobiol. 1997;  52 27-78
• 49 Dement W, Rechtschaffen A, Gulevich G. The nature of the narcoleptic sleep attack.  Neurology. 1966;  16 18-33
• 50 Broughton R, Valley V, Aguirre M, Roberts J, Suwalski W, Dunham W. Excessive daytime sleepiness and pathophysiology of narcolepsy-cataplexy: a laboratory perspective.  Sleep. 1986;  9 205-215
• 51 Guilleminault C, Wilson R A, Dement W C. A study on cataplexy.  Arch Neurol. 1974;  31 255-261
• 52 Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E. Is narcolepsy REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans.  Neurosci Res. 2000;  38 437-446
• 53 Mignot E, Lammers G J, Ripley B et al.. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.  Arch Neurol. 2002;  59 1553-1562
• 54 Fukuda K, Miyasita A, Inugami M, Ishihara K. High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan.  Sleep. 1987;  10 279-286
• 55 Bishop C, Rosenthal L, Helmus T, Roehrs T, Roth T. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness.  Sleep. 1996;  19 727-730
• 56 Ohayon M M, Priest R G, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena?.  Br J Psychiatry. 1996;  169 459-467
• 57 Aldrich M S, Chervin R D, Malow B A. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy.  Sleep. 1997;  20 620-629
• 58 Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.  Tissue Antigens. 1984;  24 316-319
• 59 Mignot E, Hayduk R, Black J, Grumet F C, Guilleminault C. HLA Class II studies in 509 narcoleptic patients.  Sleep Res. 1997;  26 433
• 60 Mignot E, Guilleminault C, Grumet F C, Dement W C. Is narcolepsy an autoimmune disease?. In: Smirne S, Francesci M, Ferini-Strambi L, Zucconi M Proceedings of the Third Milano International Symposium, September 18-19. “Sleep, Hormones, and the Immune System” Milan; Masson 1992: 29-38
• 61 Frederickson S, Carlander B, Billiard M, Link H. CSF immune variable in patients with narcolepsy.  Acta Neurol Scand. 1990;  81 253-254
• 62 Matsuki K, Juji T, Honda Y. Immunological features of narcolepsy in Japan. In: Honda Y, Juji T HLA in Narcolepsy Berlin; Springer-Verlag 1988: 150-157
• 63 Billiard M, Laaberki M F, Reygrobellet C, Seignalet J, Brissaud L, Besset A. Elevated antibodies to streptococcal antigens in narcoleptic subjects.  Sleep Res. 1989;  18 201
• 64 Montplaisir J, Poirier G, Lapierre O, Montplaisir S. Streptococcal antibodies in narcolepsy and idiopathic hypersomnia.  Sleep Res. 1989;  18 271
• 65 Mignot E, Wang C, Rattazzi C et al.. Genetic linkage of autosomal recessive canine narcolepsy with an immunoglobulin heavy-chain switch-like segment.  Proc Natl Acad Sci USA. 1991;  88 3475-3478
• 66 Chemelli R M, Willie J T, Sinton C M et al.. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.  Cell. 1999;  98 437-451
• 67 Lin L, Faraco J, Li R et al.. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.  Cell. 1999;  98 365-376
• 68 Peyron C, Faraco J, Rogers W et al.. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.  Nat Med. 2000;  6 991-997
• 69 Nishino S, Ripley B, Overeem S, Lammers G J, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy.  Lancet. 2000;  355 39-40
• 70 Nishino S, Ripley B, Overeem S et al.. Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy.  Ann Neurol. 2001;  50 381-388
• 71 Kanbayashi T, Inoue Y, Chiba S et al.. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.  J Sleep Res. 2002;  11 91-93
• 72 Krahn L E, Pankratz V S, Oliver L, Boeve B F, Silber M H. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status.  Sleep. 2002;  25 733-736
• 73 Thannickal T C, Moore R Y, Nienhuis R et al.. Reduced number of hypocretin neurons in human narcolepsy.  Neuron. 2000;  27 469-474
• 74 Ripley B, Fujiki N, Okura M, Mignot E, Nishino S. Hypocretin levels in sporadic and familial cases of canine narcolepsy.  Neurobiol Dis. 2001;  8 525-534
• 75 Ripley B, Overeem S, Fujiki N et al.. CSF hypocretin levels in various neurological conditions: low levels in narcolepsy and Guillain-Barre syndrome.  Sleep. 2001b;  24 A322
• 76 Alaila S L. Life effects of narcolepsy: measures of negative impact, social support and psychological well-being. In: Goswanmi M, Pollak CP, Cohen FL, Thorpy MJ, Kavey NB Loss, Grief and Care: Psychosocial Aspects of Narcolepsy New York; Haworth Press 1992: 1-22
• 77 De Lecea L, Kilduff T S, Peyron C et al.. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.  Proc Natl Acad Sci USA. 1998;  95 322-327
• 78 Sakurai T, Amemiya A, Ishil M et al.. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein coupled receptors that regulate feeding behavior.  Cell. 1998;  92 573-585
• 79 Peyron C, Tighe D K, van den Pol A N et al.. Neurons containing hypocretin (orexin) project to multiple neuronal systems.  J Neurosci. 1998;  18 9996-10015
• 80 Willie J T, Chemelli R M, Sinton C M, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness.  Annu Rev Neurosci. 2001;  24 429-458
• 81 Taheri S, Zeitzer J M, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy.  Annu Rev Neurosci. 2002;  25 283-313
• 82 Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy.  Prog Neurobiol. 1997;  52 27-78
• 83 Eriksson K S, Sergeeva O, Brown R E, Haas H L. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus.  J Neurosci. 2001;  21 9273-9279
• 84 Huang Z L, Qu W M, Li W D et al.. Arousal effect of orexin A depends on activation of the histaminergic system.  Proc Natl Acad Sci USA. 2001;  98 9965-9970
• 85 Yamanaka A, Tsujino N, Funahashi H et al.. Orexins activate histaminergic neurons via the orexin 2 receptor.  Biochem Biophys Res Commun. 2002;  290 1237-1245
• 86 Nishino S, Fujiki N, Ripley B et al.. Decreased brain histamine contents in hypocretin/orexin receptor-2 mutated narcoleptic dogs.  Neurosci Lett. 2001;  313 125-128
• 87 Tedford C E, Edgar D M, Seidel W F et al.. Effects of a novel, selective, and potent histamine H3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy.  Soc Neurosci Abstr. 1999;  25 1134
• 88 Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation.  Neuroreport. 2001;  12 993-997
• 89 Yoshida Y, Fujiki N, Nakajima T et al.. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities.  Eur J Neurosci. 2001;  14 1075-1081
• 90 Zeitzer J M, Buckmaster C L, Parker K J, Hauck C M, Lyons D M, Mignot E. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness.  J Neurosci. 2003;  23 3555-3560
• 91 Aston-Jones G, Chen S, Zhu Y, Oshinsky M L. A neural circuit for circadian regulation of arousal.  Nat Neurosci. 2001;  4 732-738
• 92 Wu M F, John J, Maidment N, Lam H A, Siegel J M. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement.  Am J Physiol Regul Integr Comp Physiol. 2002;  283 R1079-R1086